LLS Health signs partnership to develop one-year contraceptive vaginal system
.jpg)
The CDMO's Pathway TPUs are well-recognized as an effective option for many drug delivery systems.
The contract development and manufacturing organization (CDMO) Division of Lubrizol Life Science Health (LLS Health) is expanding its product development partnership with the Population Council, an international non-governmental, non-profit organization conducting research around critical health and development issues.
Under the partnership, LLS Health scientists will develop an optimized contraceptive vaginal system which, according to Barbara Morgan, General Manager, CDMO Division, LLS Health could be "more cost-effective" and "easier to manufacture".
This collaboration builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone, and MIV-150, and manufacturing lead formulations for toxicology.
The partnership with the Population Council reflects Lubrizol Corporation’s ‘Live Better’ mission, which pledges to improve at least 2 billion lives by 2028 through utilizing its formulating expertise, testing capabilities, market insights and global scale.
Lubrizol's Pathway thermoplastic polyurethanes (TPUs) offer controlled drug release and are compatible with a wide range of active pharmaceutical ingredients, making them an effective option for many drug delivery systems.
The project is the latest in the arena of women’s health for LLS Health, which also recently worked on the development of IPM’s Dapivirine Ring, giving women in Sub-Saharan Africa a long-acting HIV prevention option.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.